Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

It Is Cancer in Kate Middleton.

2.

findings from the measurement of disability weights in China with an emphasis on the impact of disease burden.

3.

BMTs that are "half-matched" are effective in treating severe sickle cell disease.

4.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

5.

The FDA Approves the New Frontline Aggressive ALL Regimen.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot